Related references
Note: Only part of the references are listed.Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia A Randomized Clinical Trial
Olivier Hermine et al.
JAMA INTERNAL MEDICINE (2021)
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia
Carlos Salama et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Q&A: The novel coronavirus outbreak causing COVID-19
Dale Fisher et al.
BMC MEDICINE (2020)
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
Carly G. K. Ziegler et al.
CELL (2020)
Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure
Evangelos J. Giamarellos-Bourboulis et al.
CELL HOST & MICROBE (2020)
Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection
Marie-Christine Copin et al.
INTENSIVE CARE MEDICINE (2020)
Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases
Cynthia Magro et al.
TRANSLATIONAL RESEARCH (2020)
High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients
Jean-Francois Llitjos et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients
Yonggang Zhou et al.
NATIONAL SCIENCE REVIEW (2020)
Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19
Maximilian Ackermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
Sara Mastaglio et al.
CLINICAL IMMUNOLOGY (2020)
Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome
Elizabeth A. Middleton et al.
BLOOD (2020)
Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition
Jia Yu et al.
BLOOD (2020)
Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis
Julien Carvelli et al.
NATURE (2020)
Longitudinal analyses reveal immunological misfiring in severe COVID-19
Carolina Lucas et al.
NATURE (2020)
Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients
Jerome Hadjadj et al.
SCIENCE (2020)
Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1
Justin D. Lu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome
Sujin Kang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Inborn errors of type I IFN immunity in patients with life-threatening COVID-19
Qian Zhang et al.
SCIENCE (2020)
Mannose-Binding Lectin is Associated with Thrombosis and Coagulopathy in Critically Ill COVID-19 Patients
Oskar Eriksson et al.
THROMBOSIS AND HAEMOSTASIS (2020)
Targeting complement cascade: an alternative strategy for COVID-19
Sureshbabu Ram Kumar Pandian et al.
3 BIOTECH (2020)
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Alexander P. J. Vlaar et al.
LANCET RHEUMATOLOGY (2020)
Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: A proof-of-concept study
Djillali Annane et al.
ECLINICALMEDICINE (2020)
Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation
Yoshiyasu Ueda et al.
KIDNEY INTERNATIONAL (2019)
Clinical promise of next-generation complement therapeutics
Dimitrios C. Mastellos et al.
NATURE REVIEWS DRUG DISCOVERY (2019)
Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis
Lisa E. Gralinski et al.
MBIO (2018)
Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation
Yoshiyasu Ueda et al.
BLOOD (2017)
Complement-coagulation cross-talk: a potential mediator of the physiological activation of complement by low pH
Hany Ibrahim Kenawy et al.
FRONTIERS IN IMMUNOLOGY (2015)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
A novel c5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways
Konstantinos Ritis et al.
JOURNAL OF IMMUNOLOGY (2006)
Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis
I Hamming et al.
JOURNAL OF PATHOLOGY (2004)
Share Paper
